Corcept Therapeutics (NASDAQ: CORT) reported Q2 EPS of $0.24, $0.02 better than the analyst estimate of $0.22. Revenue for the quarter came in at $103.4 million versus the consensus estimate of $100.62 million.

GUIDANCE:

Corcept Therapeutics sees FY2022 revenue of $400-430 million, versus the consensus of $414.4 million.

For earnings history and earnings-related data on Corcept Therapeutics (CORT) click here.